Elaine Shum, MD, discusses consulting patients with non-small cell lung cancer on the use of osimertinib.
Elaine Shum, MD, an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, discusses consulting patients with non–small cell lung cancer (NSCLC) on the use of osimertinib (Tagrisso).
The primary end point of the phase 3 ADAURA trial was looking at patients with stage II and III NSCLC, as well as those with stage IB disease, says Shum. An impressive hazard ratio for disease-free survival of 0.17 was observed in that group of patients, says Shum. This trial should be discussed with patients who have had resected lung cancer with an EGFR mutation, according to Shum. For patients with stage II or III disease, it's definitely an option that can be pursued, says Shum.
For those with stage IB lung cancer, adjuvant chemotherapy is an option, although there is no set standard as to who receives it and who does not. In the clinic, having a discussion with the patient about whether or not to use osimertinib for 3 years for stage IB resected NSCLC is needed, concludes Shum.